MCN36 (nutritional supplement)

Phase 2Small molecule

MCN36 (nutritional supplement) is one of 46 small molecule programs targeting Bipolar Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bipolar DisorderTerminated

Bipolar DisorderPhase 2

Terminated

Competition

Competitive Landscape

192 competitors in Bipolar Disorder

#DrugCompanyPhaseTrials

Depacon

AbbVie

Phase 3

6 2

Depakote

AbbVie

Phase 3

5 3

Depakote

AbbVie

Phase 3

5 4

Robitussin

Pfizer

Phase 3

2 5

Paxil

SSebela Pharmaceuticals Development LLC

Phase 3

3 6

Ketalar

Boehringer Ingelheim

Phase 3

2 7

Methylthioninium Chloride

PProvepharm SAS

Phase 3

1 8

Rescue

Merck & Co.

Phase 3

2 9

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Bupropion XL

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bipolar Disorder1 trial

Randomized Placebo-controlled Phase II Trial of MCN36 in Adults With Bipolar Disorder

Terminated·UUniversity of Calgary·Phase 2·NCT00109577·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for MCN36 (nutritional supplement). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MCN36 (nutritional supplement) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MCN36 (nutritional supplement). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Calgary company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Calgary

MCN36 (nutritional supplement)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bipolar Disorder1 trial

References

Drug Info

Quick Facts

Related News